KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Receivables data on record, last reported at $524.4 million in Q3 2025.

  • For Q3 2025, Receivables rose 4.69% year-over-year to $524.4 million; the TTM value through Sep 2025 reached $524.4 million, up 4.69%, while the annual FY2024 figure was $636.6 million, 48.01% up from the prior year.
  • Receivables reached $524.4 million in Q3 2025 per SRPT's latest filing, down from $600.6 million in the prior quarter.
  • Across five years, Receivables topped out at $714.6 million in Q1 2025 and bottomed at $133.3 million in Q1 2021.
  • Average Receivables over 5 years is $346.3 million, with a median of $285.8 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 97.37% in 2023, then grew 4.69% in 2025.
  • A 5-year view of Receivables shows it stood at $153.0 million in 2021, then soared by 42.42% to $217.9 million in 2022, then soared by 97.37% to $430.1 million in 2023, then skyrocketed by 48.01% to $636.6 million in 2024, then dropped by 17.62% to $524.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $524.4 million in Q3 2025, $600.6 million in Q2 2025, and $714.6 million in Q1 2025.